36results about How to "More palatable" patented technology

The invention relates to dried milk protein concentrates and their use. In particular the invention relates to such dried concentrates which have been calcium-depleted to an extent which allows improvements in the use of dried milk protein concentrates in cheese manufacture. The invention includes a method of cheese manufacture comprising: (a) dispersing in milk a dried MPC or MPI having at least 70% dry matter as milk protein; (b) treating the resulting mixture with one or more coagulating enzymes to produce a curd; and (c) processing the curd to make cheese; wherein the dried MPC or MPI is a calcium-depleted MPCF or MPI and the extend of calcium depletion is sufficient to allow manufacture of substantially nugget-free cheese.

This invention provides dry composites to, e.g., efficiently deliver unmodified amino acids, lipids, and/or feed supplements through the upper digestive tract of an animal. The invention also provides methods and systems to make and use protected dry composites.

The present invention relates to compositions for supplementing the diet of subjects suffering from cardiovascular or peripheral vascular disease or those at risk for such conditions. Ribose is given alone or in combination with one or a combination of vasodilators, nutrients and vitamins. Preferred vitamins include Vitamins C, B6, B12 and folic acid. Preferred nutrients include glutamine and glucose.

A method and implement for use in speech therapy to assist with teaching a patient to correctly produce sounds, especially /r/ sounds, designed to be used in a human mouth to support tongue tip and made of a palatable, non-toxic substance such as wax or candy.

A highly concentrated preparation of sodium 4-phenylbutyrate in an aqueous medium as an alternative for present high dosage therapeutic treatments of certain disorders is provided, specifically for the treatment of spinal muscular atrophy (SMA), central nervous system (CNS) cancer, myelodysplastic syndrome (MS), acute leukemia, glioblastoma multiforme, amyotrophic lateral sclerosis (ALS), and colon cancer.

The invention provides a dried milk protein concentrate which has high denatured whey protein content and is calcium depleted. Processes for preparing the product are also provided. The product is useful in preparing cheese, particularly for reducing the formation of nuggets (thin protein rich gels of a different colour) in the cheese. In one embodiment the calcium content of a milk protein concentrate is reduced and whey proteins are denatured using heat treatment, prior to drying, to obtain the product.

A formulation for administration of a medicinal substance, comprises a sandwich biscuit having two or more biscuit layers that support filler layer(s), in which the filler layer comprises a dosage unit form, or a multiple or sub-multiple thereof, of a medicament that is unpalatable in having, for example, a gritty texture or a chalky texture or other unpleasant mouth feel. The biscuit layer of the sandwich biscuit may be a plain, non-medicated, biscuit layer or may itself contain a medicament. In the latter instance, it is possible to select a different medicament for the filler layer from that in the biscuit layer, whereby the two medicaments have a co-operating or synergistic effect. The formulations also allow large dosages of drugs to be administered effectively in a palatable form and are suitable for the long-term administration of drugs.

A process for thickening liquid food and/or medications of people with swallowing problems which involves dilution of a concentrate thickener paste which has been thickened to several times its normally useful and cost-effective levels. The approach is beneficial in formulations intended for radiological evaluations of people with swallowing problems including those persons suffering from dysphagia.

A process for preparing a stable aqueous dosage form of sodium 4-phenylbutyrate, including such dosage forms in a highly concentrated solution, as well as methods for making 4-phenylbutyrate and 4-phenylbutyric acid, and for using 4-phenylbutyrate. The stable aqueous dosage forms do not freeze at 0° C.

Compositions in which aspirin is present in combination with alkaline compounds, especially those containing water of crystallization (hydrates), deteriorate on standing. This deterioration may take several forms: It can be a physical deterioration in which such aspirin compositions become completely unmanageable, wet, gummy, sticky masses; or chemical decomposition in which aspirin loses its molecular structure chiefly by losing the acetyl group. The latter is accompanied by formation of acetic acid, the mixture developing its characteristic acetic odor. In both cases, such compositions become entirely unsuitable for all practical commercial and medicinal purposes. Yet, when preparation of water-soluble aspirin compositions is desired, it is impossible to avoid the use of alkaline compounds. This is because the only known method of converting aspirin into soluble form is by means of reacting it with an alkaline compound to form the soluble salt of aspirin. Unexpectedly, it was discovered and is the substance of the present invention that there are two compounds both of which are alkaline and contain water of crystallization (hydrates), and which, in combination with aspirin, give soluble compositions of outstanding stability. Unexpectedly, it was discovered and is also the substance of the present invention that there are several sugar substitutes which have demonstrated an acceleration of absorption into the bloodstream and have demonstrated a reduction in acididity which in turn should reduce or eliminate the potential for bleeding in the stomach. These two compounds are sodium citrate (tri) dihydrate, and potassium citrate (tri) monohydrate. Artificial sweeteners can also be combined in the soluble aspirin composition.

The present invention relates generally to plant extracts and/or components isolated therefrom which exhibit desirable properties in relation to therapy and/or food technology. More particularly, the present invention relates to extracts and components isolated thereof from the plant genus Zingiber and in particular from the rhizome of the species Zingiber officinale (also known as ginger) which comprise activities having broad applicability in the fields of research reagents, inter alia pharmaceutical and/or nutraceutical product development, manufacture of improved high-value food and feed products, production of alcohol from cereals and waste treatment.

A frozen confection or a beverage product is provided which contains at least 400 mg of theobromine and at least 40 mg of caffeine per 100 grams of the product. Also provided is a frozen confection or a beverage product for the enhancement of mood without transient elevation of blood pressure.

An edible animal chew for animals, particularly dogs, resembling a naturally occurring substantially unprocessed food source, such as a vegetable, grain, fruit, or animal, in its nutritional content and in one or more of its shape, color, or texture, and wherein the size, hardness, or flavoring of the chew may be changed to accommodate an animal with regard to, for example, the animal's type, age, or size.

The present invention provides a non-parenteral and non-ocular herbal synergistic detoxifier composition effective for blood purification, blood detoxification and in the treatment and management of disorders related to accumulation of toxins in the body having synergistic effect of its components in specific ratio, better bio availability wherein the amount of dose administered is remarkably low. The formulation of synergistic herbal composition has better patient compliance in the terms of palatability, ease of administration and is formulated in the form of syrup, lozenges/candies/jujubs/mouth freshener, sub-lingual tablets or chewable tablets. The present invention also provides a method of preparation of this formulation.

A novel class of thermal hysteresis (antifreeze) proteins (THP) that have up to 100 times the specific activity of fish antifreeze proteins has been isolated and purified from the mealworm beetle, Tenebrio molitor. Internal sequencing of the proteins, leading to cDNA cloning and production of the protein in bacteria has confirmed the identity and activity of the 8.4 to 10.7 kDa THP. They are novel Thr- and Cys-rich proteins composed largely of 12-amino-acid repeats of cys-thr-xaa-ser-xaa-xaa-cys-xaa-xaa-ala-xaa-thr. At a concentration of 55 μg/mL, the THP depressed the freezing point 1.6° C. below the melting point, and at a concentration of ˜1 mg/mL the THP or its variants can account for the 5.5° C. of thermal hysteresis found in Tenebrio larvae. The THP function by an adsorption-inhibition mechanism and produce oval-shaped ice crystals with curved prism faces.

A calcium supplement for animals comprising one or more coatings over a calcium-containing core. The coatings provide additional nutrients as well as providing a moisture-resistant outer coating to reduce the hygroscopic effects of the calcium-containing core. The supplement comprises calcium-containing core particles, calcium chloride for example, each particle having an animal nutrient coating over an outer surface of the core particles. The supplement further comprises a second coating, urea, deposited over the nutrient coating, and a final outer coating comprising one or more fatty acids or paraffinic hydrocarbons that are agreeable to animals. The method for making a calcium supplement for animals comprises coating calcium-containing granules with a layer of nutrients and then spraying molten soluble urea onto the previously coated calcium-containing granules which are sufficiently cool to solidify the molten material into second coating on the granules. A third coating of one or more fatty acids or paraffinic hydrocarbon is sprayed onto the urea coating.

A composition for stimulating muscle growth, comprising an effective amount of L-arginine or a salt thereof, a pH control agent for controlling the pH at less than 7 and a pharmaceutically acceptable carrier. A method of using the composition to achieve muscle growth or an immune response is also described.